Genentech pays Alector $100M upfront for brain-penetrant GCase therapy AL050
- Alector licensed AL050, a preclinical brain-penetrant engineered GCase enzyme replacement therapy for Parkinson's disease, to Genentech.
- The deal brings $100M upfront, up to $1.17B in milestones and tiered royalties; Genentech takes development, manufacturing and commercialization.
- Alector keeps its Brain Carrier platform, and the cash extends its runway into 2029.
💡 Points
A $100M upfront for a preclinical asset shows how much Roche values a validated blood-brain barrier shuttle in GBA1-linked Parkinson's. For Alector, it's a lifeline that funds its Alzheimer's and siRNA programs. The risk is that delivery, not the enzyme, is the real bet, and Genentech has other shuttle options.
Genentech pays Alector $100M for preclinical Parkinson's prospect ↗